Clinical Trials Browser

Bile Duct Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Nasopharyngeal Carcinoma

Bone Neoplasms, Melanoma, Osteosarcoma, Urologic Neoplasms

Biliary Tract Neoplasms

Metastatic Pancreatic Ductal Adenocarcinoma

Gallbladder Cancer Unresectable

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Lung Neoplasms

Biliary Tract Neoplasms

Locally Advanced Pancreatic Cancer

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

Urinary Bladder Neoplasms

Biliary Tract Neoplasms

Cholangiocarcinoma

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease

Pancreatic Neoplasms, Neoplasms, Basal Cell

Cholangiocarcinoma

Leukemia, Myeloid, Acute

Bile Duct Neoplasms, Cholangiocarcinoma

Pancreatic Neoplasms

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Pancreatic Neoplasms

Triple Negative Breast Neoplasms

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

Hodgkin Disease, Recurrence

Cholangiocarcinoma

Phase 2 Study

Carcinoma, Transitional Cell

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Pancreatic Neoplasms

Neoplasm Metastasis

Pancreatic Adenocarcinoma

Pancreatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms

Lymphoma, Large B-Cell, Diffuse

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

Clinical Trials

Ablatio

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

LIGHT

Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases

SAFIR-ABC10

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

GCND

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

DOVE

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer

Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma

LAP100

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

PANGEA

Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery

PARPAML

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Study of Lacutamab in Peripheral T-cell Lymphoma

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

ADAPT-BLADDER

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients

Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer

SWITCH

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer

GAIN-BCG

IMMUNOLIFE2

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial